Toxicological evaluation is important at every stage of HPAPI development and manufacturing—CDMOs help ensure new treatments are brought to market safely.
Each year, pharmaceutical manufacturers spend millions of dollars on engineering controls to prevent employee exposure to HPAPIs, but in many cases, these controls fail to deliver the desired results . . .